Track topics on Twitter Track topics that are important to you
The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...
KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...
AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...
BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...
Regulus Therapeutics San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...
http://stock-callers.com/registration Celldex Therapeutics On Thursday, shares in Hampton, New Jerseyheadquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, whi...
Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of thera...
NewsMagenta Therapeutics aspires to develop a patient-focused set of therapeutics with the first complete platform that addresses the critical challenges in stem cell transplant.
http://stock-callers.com/registration PTC Therapeutics At the close on Tuesday, shares in South Plainfield, New Jerseyheadquartered PTC Therapeutics Inc. dropped 3.06%, ending the day at Read...
Sosei Group's subsidiary Heptares Therapeutics has agreed to acquire Swiss drugmaker G7 Therapeutics for CHF12m ($11.8m).
Bicycle Therapeutics, which is pioneering a new class of therapeutics based on its proprietary bicyclic…
Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).